


- <sup>12</sup> EIMS = Electron Impact Mass Spectrometry; CIMS = Chemical Ionization Mass Spectrometry.

significant intensity), forms a diacetate,  $C_{32}H_{50}N_2O_4$ , m.p. 186–189°,  $\nu_{max}^{CH_3}$  3440, 1720, 1660, 1510 and 1440  $cm^{-1}$ ,  $\delta_{max}^{CH_3}$  1.95 (s), EIMS  $M^+$  526, when reacted with  $Ac_2O$ /pyridine for 18 h at 65°, followed by chromatography. When treated with sodium borohydride/formaldehyde in the modern version of the Eschweiler-Clark reaction<sup>13</sup>, solacasine was converted to a tri-N-methyl dihydro analog **4**,  $C_{31}H_{54}N_2O_2$ , (EIMS<sup>12</sup>,  $M^+$  486(5%), 471(12%), 454( $M^+-CH_3OH$ , 53%), etc.) Reaction of solacasine with  $NaBH_4$  alone led to a dihydro derivative **2**,  $C_{28}H_{48}N_2O_2$ , EIMS<sup>12</sup>  $M^+$  444(9%), 429(22%), 412( $M^+-MeOH$ , 64%), 343(10%), 171(100%), 144(11%), 139(18%), 112(21%), 111(24%), 82(20%), 70(46%), 56(25%), etc., picrate salt, m.p. 178–182°. The common loss of methanol from the molecular ion in the mass spectra of these derivatives, coupled with an analogous loss of water by solanocapsine in its EIMS<sup>12</sup> ( $M^+$  430 (7%), 412 ( $M^+-HOH$ , 100%)) and CIMS<sup>12</sup> (*i*-BuH)  $MH^+$  431 (100%), 413 ( $MH^+-HOH$  20%) no other significant peaks), the general similarity in spectra and properties suggested structure **3** as most likely for solacasine. Further support can be found in the fragmentation patterns. The mass spectra of steroidal alkalamines are complex<sup>14</sup>, but the presence or absence of certain fragments has diagnostic value. In particular cleavages a) and b) reveal a great deal about the structure of rings A and B. In this context, the presence of signi-



ficant ions at  $m/e$  56 and 82 in the EIMS of **1**, **2** and **3**, and the lack of pairs of ions at  $m/e$  70 and 96 in the same, argue that the 'extra' methyl group of **3** is unlikely to be attached to a carbon of either ring A or B and that the point of unsaturation must also be elsewhere. Ions  $m/e$  84(55%) and 110(20%) in the EIMS of the Eschweiler-Clark product are consistent with that view as are their relative intensities (2:1)<sup>14</sup>.

These inferences received strong support when solacasine and solanocapsine were converted to a common intermediate (**2**). Solanocapsine (**1**) was dissolved in cold, dry methanol and a slow stream of dry HCl gas was introduced intermittently over 22 h at which time no more **1** was present upon TLC examination. Two main products were separated by sephadex LH-20 and silica gel chromatography. The more major of these two had identical TLC mobility in mixed spot experiments in 5 systems, an identical mass spectrum (EIMS), and formed an identical picrate salt (m.p. and IR-spectrum) when compared with **2** prepared by hydride reduction of **3**. The remaining point of uncertainty in the structure is the stereochemistry of the ketal moiety in **3**, but otherwise these experiments are rationalized by this formulation for solacasine.

The in vitro antimicrobial activity of these materials, using an agar-dilution streak assay<sup>15</sup>, is as follows:

Microorganism	Compound			
	1	2	3	4
<i>Staphylococcus aureus</i> (6538P) <sup>a</sup>	100 <sup>b</sup>	100	12.5	100
<i>Mycobacterium smegmatis</i> (607B)	100	100	5.0	100
<i>Candida albicans</i> (10231)	100	50	2.5	50

<sup>a</sup>American type culture collection number. <sup>b</sup> $\mu g/ml$ .

The relatively small structural difference between **1** and **3** is nonetheless accompanied by a large difference in antibacterial potency. In vivo evaluation of **3** is in progress. The other agents are not potent enough to warrant further study.

<sup>13</sup> M. TOMITA and M. KOZUKA, *Yakugaku Zasshi* 87, 1134 (1967).

<sup>14</sup> H. BUDZIEKIEWITZ, C. DJERASSI and D. H. WILLIAMS, *Structure Elucidation of Natural Products by Mass Spectrometry* (Holden-Day, Inc., San Francisco 1964), vol. 2, pp. 5–23 and 74–80.

<sup>15</sup> L. A. MITSCHER, R.-P. LEU, M. S. BATHALA, W.-N. WU J. L. BEAL and R. WHITE, *Lloydia* 35, 157 (1972).

### (–)-8β-Hydroxymethyl-Δ<sup>1</sup>-Tetrahydrocannabinol: A Novel Physiologically Active Analog of Δ<sup>1</sup>-Tetrahydrocannabinol<sup>1</sup>

R. K. RAZDAN, J. F. HOWES, D. B. ULISS, H. C. DALZELL, G. R. HANDRICK and W. L. DEWEY<sup>2</sup>

Sheehan Institute for Research, Inc., 767 B Concord Avenue, Cambridge (Massachusetts 02138, USA); and Medical College of Virginia, Richmond (Virginia 23298, USA), 3 November 1975.

**Summary.** (–)-8β-Hydroxymethyl-Δ<sup>1</sup>-tetrahydrocannabinol (THC) **1**, a novel analog of Δ<sup>1</sup>, is shown to be as active as Δ<sup>1</sup>-THC and twice as active as Δ<sup>1(6)</sup>-THC in the dog ataxia test.

We have recently reported<sup>3</sup> the synthesis of (–)-8β-hydroxymethyl-Δ<sup>1</sup>-tetrahydrocannabinol (THC) (**1**), a novel analog of Δ<sup>1</sup>-THC. In that paper, we stated that compound **1** exhibited THC-like overt central nervous systems (CNS) symptomatology in rodents at 1.0 mg/kg (i.v.). In the present communication, we confirm these results and compare the activity of **1** with Δ<sup>1</sup>- and Δ<sup>1(6)</sup>-THC's in mice and dogs, and show that, in the latter, compound **1** is at least as active as Δ<sup>1</sup>-THC and twice as active as Δ<sup>1(6)</sup>-THC. This is the first example of a

modification in the geminal methyl part of the molecule of Δ<sup>1</sup>-THC, although a few examples have been reported in the Δ<sup>3,4</sup>-THC series. The activity of **1** is noteworthy, since in the Δ<sup>3,4</sup>-THC's it has been shown that the geminal methyl group affords optimum activity<sup>4–6</sup>. However, no similar hydroxymethyl derivative is known in the Δ<sup>3,4</sup>- series for a direct comparison with **1**.

Δ<sup>1</sup>-THC and other cannabinoids produce a characteristic effect in dogs, which includes static and dynamic ataxia, hyperflexia and decreased activity. This dog